FDA approves ziftomenib to treat some relapsed leukemia patients
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1…
Blood cancer
Blood cancer overview
Blood cancer is a broad term encompassing diseases in which blood cells grow too much or develop abnormally. Typically, blood cancers are classified into three main categories – leukemia, lymphoma, and myeloma – but they can be further divided into dozens of specific types, each with unique features.
Read moreTreatments for blood cancers
A wide range of therapies are available for treating blood cancer, from chemotherapy and targeted therapy to radiation, stem cell transplant, and surgery. When devising a suitable treatment plan for blood cancer, healthcare providers take into account various factors, such as age, overall health, the specific type of blood cancer, and potential treatment side effects.
Read moreLatest news
CAR T-cell therapy candidate yields lasting response in tough lymphoma
One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with hard-to-treat large B-cell lymphoma (LBCL).
Cero seeking more safety, dosing data on T-cell therapy for AML
A third dose of CER-1236, Cero Therapeutics’ T-cell therapy candidate for acute myeloid leukemia (AML), was administered to an AML patient taking part in…
FDA approves Revuforj for AML with NPM1 mutations
The U.S. Food and Drug Administration (FDA) has approved Syndax‘s oral therapy Revuforj (revumenib) as a treatment for certain people with acute myeloid leukemia…
All 3 patients in trial to date see benefits with treatment for AML
All three adults with high-risk acute myeloid leukemia (AML) who had already been given 3-4 lines of cancer treatment responded to a combination of Venclexta…
Kernal Bio awarded up to $48M to develop blood cancer treatments
The Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $48 million to Kernal Bio to support the development of more efficient,…
